AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
about
Targeting the Pim kinases in multiple myelomaTargeting Pim kinases for cancer treatment: opportunities and challengesPim-1 kinase as cancer drug target: An updateLifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeuticsTargeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subsetPIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancerComputational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer.Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.Control of Pim2 kinase stability and expression in transformed human haematopoietic cellsIncreased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemiaThe PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cellsConstitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signalingAcquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.FLT3 inhibitors: clinical potential in acute myeloid leukemia.Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.Pim kinases in hematological malignancies: where are we now and where are we going?Targeted therapy of acute myeloid leukemia.PIM kinase (and Akt) biology and signaling in tumors.Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Eosinophil resistance to glucocorticoid-induced apoptosis is mediated by the transcription factor NFIL3.Design and Synthesis of Potent and Selective PIM Kinase Inhibitors by Targeting Unique Structure of ATP-Binding Pocket.Synthesis of new pyridothienopyrimidinone derivatives as Pim-1 inhibitors.The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208.Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia.Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.Regulation of prostate stromal fibroblasts by the PIM1 protein kinase.PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.PIM1: a promising target in patients with triple-negative breast cancer.
P2860
Q26799499-2B4BAB40-52EB-4BE4-B6ED-154077DB6957Q28255361-8DF99212-57C7-43F9-AE9C-10A856944490Q28273475-5A888889-4CAD-4AC3-B91D-AC702F3F89A2Q28543966-82B68D8F-86D4-4252-A9F7-835BDDB95588Q33728277-3621128F-538B-45D3-94DD-D9C70C538787Q34489388-106EDF3C-28B4-4DE5-AC4E-841AB9F35B05Q35078578-52F723CC-5B2A-45A4-8DD9-216DCB4C25A1Q35573363-B14A0C0A-E01B-47B3-B1AC-4F2AAF373E49Q35852684-B9CFAE5A-8B61-40CB-B4FF-FBDDA78B0B07Q36276942-4EE02569-452B-4C9E-956E-0785FF484DAFQ36353641-1019316D-6408-4A8A-B443-1F6E51B9CCCEQ36413237-630F1703-D2EF-4020-9D4B-DCE5039D3228Q36545566-7ED828AE-2E5D-4DAD-9926-81DF90C597BFQ36746585-343F266C-FAFC-4E9E-9BFD-05DDA5A88D0BQ36920449-5E731AA8-E931-42F7-ACD4-3BD52C965C9DQ37233255-E48E6DF1-A5C4-40EE-A1D1-DBD911E051BBQ37362875-CE0DB95B-BF5D-45B5-8A3A-67C372FD4D8FQ37437166-95B0F55C-0238-46E5-8561-7DF966C7A0C6Q37628915-E68E6198-FFAF-4A13-B431-44EBDC3A22ACQ37638749-B126B336-016D-456A-BA09-501D460C9C37Q38261268-04C8D870-7B48-4D86-B6ED-007F9B27D026Q38262117-3CCE83E7-7D3C-43C2-8C58-3CC5EF7BCAE4Q38285805-D8AC3B5C-431F-4C35-9B79-71A09A75A091Q38333251-A823EF0F-241E-45B2-BBA1-E8AA8C6D2C08Q38370023-899CCA7F-56D5-42DE-8146-4AEBBC2FD34DQ38401664-11632CDE-494F-4488-BD1A-E87FD5A70D5DQ38417153-CA2BB43E-9452-4D7D-AE4C-6F68DCE5D129Q38681971-E9B9D0A4-62DC-47CC-9348-26B16BFD0B86Q38720833-B7B1338C-C7A4-4CA4-B1C8-D4043FDB3047Q38728157-4A9AC339-A798-49E0-97D4-D364D3BD315FQ38735131-376C87E4-A512-4512-9DF4-3619102CD211Q38769889-20D0A75F-BB78-4208-A9E9-27407892D373Q38770271-748C4206-0CA5-44E4-9F48-67142073138BQ38798340-6BE062D8-969D-4F76-A03B-2A2924829A63Q38803880-9FDBDC1A-78AD-40CC-8FB1-ED3A65C04FBBQ38813901-8B8F69AF-6B0C-477B-A11D-390EBFDC7499Q38934636-2E55F3D8-BA5F-4882-863E-73EB6BFD0DB1Q38979939-320A74A7-6BDF-4192-8C29-3F5880182845Q39253133-27E14361-95D3-4A30-A3F6-C7422660A2C4Q39443294-AB37309F-9B1E-4FDF-B2F5-C1C8A426FDF3
P2860
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.
@en
AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.
@nl
type
label
AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.
@en
AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.
@nl
prefLabel
AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.
@en
AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.
@nl
P2093
P2860
P1433
P1476
AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.
@en
P2093
Daniel J Deangelo
Dennis Huszar
Erika K Keeton
Francis D Gibbons
Huawei Chen
Keith S Dillman
Kristen McEachern
Leonidas C Platanias
Les A Dakin
P2860
P304
P356
10.1182/BLOOD-2013-04-495366
P407
P577
2013-12-20T00:00:00Z